z-logo
Premium
MUC1 and MUC2 expression in salivary gland tumors and in non‐neoplastic salivary gland tissue
Author(s) -
MANNWEILER SEBASTIAN,
BEHAM ALFRED,
LANGNER CORD
Publication year - 2003
Publication title -
apmis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 88
eISSN - 1600-0463
pISSN - 0903-4641
DOI - 10.1034/j.1600-0463.2003.1111010.x
Subject(s) - salivary gland , muc1 , pathology , mucin , submandibular gland , serous fluid , sublingual gland , adenoid cystic carcinoma , immunohistochemistry , mucoepidermoid carcinoma , pleomorphic adenoma , mucin 2 , biology , medicine , carcinoma , gene expression , biochemistry , gene
The expression of MUC1 and MUC2 was studied in salivary gland tumors and non‐neoplastic salivary gland tissue. Formalin‐fixed paraffin‐embedded specimens from 101 patients (21 pleomorphic adenomas (PA), 22 Warthin's tumors (WT), 26 adenoid cystic carcinomas (ACC), 13 acinic cell adenocarcinomas (ACA), 9 mucoepidermoid carcinomas (MC), and 10 specimens of non‐neoplastic parotid and submandibular gland tissue) were immunostained. All salivary gland tumors expressed MUC1. A strong immunoreactivity was noted in WT and MC, a moderate in ACC and ACA, and a weak in PA. Strong expression of MUC2 was noted in all WT, moderate expression in MC, and weak expression in PA and ACA. All cases of ACC except for two were negative for MUC2. In general, MUC1 expression was stronger than that of MUC2. Non‐neoplastic salivary gland tissue revealed a moderate MUC1 and MUC2 expression in excretory ducts and a strong expression in striated ducts. The apical plasma membrane of some serous acini expressed MUC1. Mucous acini were negative for both antigens. No change in immunoreactivity was noted in cases of chronic sclerosing sialadenitis. In conclusion, the different expression pattern of MUC1 and MUC2 in salivary gland neoplasia may be of additional value for the classification of salivary gland tumors.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here